Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the FDA.

Industry experts have provided insight into how oncology clinical trials can be designed for success from the outset and rendered as patient-centric as possible.

Viatris’ investigational blepharitis ointment failed to achieve the primary endpoint in its Phase III trial, prompting the company to reconsider the drug’s future. The Phase III study (NCT06400511) ...

MSD unveiled the launch of the Phase III trials of MK-8527 at the International AIDS Society (IAS) 2025 conference.

Novartis is stopping the development of ianalumab in hidradenitis suppurativa (HS) after a Phase IIb proof-of-concept trial failed to meet its primary endpoint.

OKYO Pharma has reported encouraging top-line outcomes from the randomised Phase II trial of urcosimod to treat NCP.

Hengrui Pharma and Kailera Therapeutics have reported positive topline data from the former’s Phase III trial (HRS9531-301) of HRS9531.

The growing prevalence of prediabetes among children and adolescents suggests that unhealthy, inactive lifestyles are increasing in the US.

UroMems is set to enter the pivotal trial phase with its device for treating stress urinary incontinence (SUI).

UK & Ireland, experts provided insights on market trends within the clinical trial industry and advice on engagement strategies.

The UK MHRA has granted approval for Cybin to initiate the EMBRACE study to assess CYB003 for the adjunctive treatment of MDD.